New Delhi: The Supreme Court has sought responses from the Union of India, the Drug Controller General of India (DCGI), and several leading pharmaceutical companies, including Bharat Serum and Vaccines, Cipla, Sun Pharma, Emcure, and Natco Pharma, on a public interest litigation questioning the continued manufacture and sale of Liposomal Amphotericin B, a drug originally cleared for emergency use during the Covid-19 pandemic.

According to a LiveLaw report, a Bench of Justices Vikram Nath and Sandeep Mehta on Friday issued notice to the Centre on the plea, which also calls for the destruction of existing stocks of the drug, citing expired authorizations and potential safety risks.

A Bench of Justices Vikram Nath and Sandeep Mehta sought responses from the Union of India, the Drug Contr

See Full Page